iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/31416508
[Clinical effect of azithromycin adjuvant therapy in children with bronchiolitis: a systematic review and Meta analysis] - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Aug;21(8):812-819.
doi: 10.7499/j.issn.1008-8830.2019.08.014.

[Clinical effect of azithromycin adjuvant therapy in children with bronchiolitis: a systematic review and Meta analysis]

[Article in Chinese]
Si-Yi Che  1 , Huan He, Yu Deng, En-Mei Liu
Affiliations
Meta-Analysis

[Clinical effect of azithromycin adjuvant therapy in children with bronchiolitis: a systematic review and Meta analysis]

[Article in Chinese]
Si-Yi Che et al. Zhongguo Dang Dai Er Ke Za Zhi. 2019 Aug.

Abstract
in English, Chinese

Objective: To systematically evaluate the clinical effect of azithromycin (AZM) adjuvant therapy in children with bronchiolitis.

Methods: Related databases were searched for randomized controlled trials (RCTs) on AZM adjuvant therapy in children with bronchiolitis published up to February 17, 2019. RevMan 5.3 was used to perform the Meta analysis.

Results: A total of 14 RCTs were included, with 667 children in the intervention group and 651 in the control group. The pooled effect size showed that in the children with bronchiolitis, AZM adjuvant therapy did not shorten the length of hospital stay (MD=-0.29, 95%CI: -0.62 to 0.04, P=0.08) or oxygen supply time (MD=-0.33, 95%CI: -0.73 to 0.07, P=0.10), while it significantly shortened the time to the relief of wheezing (MD=-1.00, 95%CI: -1.72 to -0.28, P=0.007) and cough (MD=-0.48, 95%CI: -0.67 to -0.29, P<0.00001). The analysis of bacterial colonization revealed that AZM therapy significantly reduced the detection rates of Streptococcus pneumoniae (OR=0.24, 95%CI: 0.11-0.54, P=0.0006), Haemophilus (OR=0.28, 95%CI: 0.14-0.55, P=0.0002), and Moraxella catarrhalis (OR=0.21, 95%CI: 0.11-0.40, P<0.00001) in the nasopharyngeal region.

Conclusions: AZM adjuvant therapy can reduce the time to the relief of wheezing and cough in children with bronchiolitis, but it has no marked effect on the length of hospital stay and oxygen supply time.

目的: 系统评价阿奇霉素（AZM）辅助治疗儿童毛细支气管炎的有效性。

方法: 采用RevMan 5.3软件，对截止2019年2月17日国内外发表的关于AZM用于辅助治疗毛细支气管炎的临床随机对照试验进行Meta分析。

结果: 共纳入14篇文献，干预组667例，对照组651例。合并效应量结果显示，AZM辅助治疗不能缩短毛细支气管炎患儿的住院时间（MD=-0.29，95% CI：-0.62~0.04，P=0.08）及用氧时间（MD=-0.33，95% CI：-0.73~0.07，P=0.10）；可以缩短患儿喘息（MD=-1.00，95% CI：-1.72~-0.28，P=0.007）及咳嗽缓解时间（MD=-0.48，95% CI：-0.67~-0.29，P < 0.00001）。菌群分析结果提示，AZM能有效减少患儿鼻咽部肺炎链球菌（OR=0.24，95% CI：0.11~0.54，P=0.0006）、嗜血杆菌属（OR=0.28，95% CI：0.14~0.55，P=0.0002）和卡他莫拉菌（OR=0.21，95% CI：0.11~0.40，P < 0.00001）的检出率。

结论: AZM辅助治疗儿童毛细支气管炎一定程度上有助于缩短患儿咳嗽及喘息缓解时间，但对住院及用氧时间的影响不显著。

PubMed Disclaimer

Figures

1
1
AZM对住院时间的影响
2
2
AZM对用氧时间的影响
3
3
AZM对喘息缓解时间的影响
4
4
AZM对咳嗽缓解时间的影响
5
5
AZM对肺炎链球菌检出率的影响
6
6
AZM对嗜血杆菌属检出率的影响
7
7
AZM对卡他莫拉菌检出率的影响
8
8
AZM对金黄色葡萄球菌检出率的影响
9
9
基于住院时间的漏斗图
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Paramore LC, Ciuryla V, Ciesla G, et al. Economic impact of respiratory syncytial virus-related illness in the US:an analysis of national databases. Pharmacoeconomics. 2004;22(5):275–284. doi: 10.2165/00019053-200422050-00001. - DOI - PubMed
    1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015:a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi: 10.1016/S0140-6736(17)30938-8. - DOI - PMC - PubMed
    1. Caffrey Osvald E, Clarke JR. NICE clinical guideline:bronchiolitis in children. Arch Dis Child Educ Pract Ed. 2016;101(1):46–48. doi: 10.1136/archdischild-2015-309156. - DOI - PubMed
    1. Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, et al. Azithromycin:mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143(2):225–245. doi: 10.1016/j.pharmthera.2014.03.003. - DOI - PubMed
    1. Hosakote YM, Jantzi PD, Esham DL, et al. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2011;183(11):1550–1560. doi: 10.1164/rccm.201010-1755OC. - DOI - PMC - PubMed